

# Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

NCT06739395

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Tianjin Medical University Second Hospital
Enrollment	300 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Recurrent or metastatic malignant solid tumors diagnosed by histology or cytology;
- ECOG score 0-4 (3-4 points only for patients with tumor burden);
- Those who fail or cannot tolerate standard treatment, or those who refuse standard treatment;
- At least one measurable lesion that meets the RECIST 1.1 standard;
- Expected survival period e 3 months;

... and 3 more (see full listing online)

### Exclusion (3)

- Patients who have actively undergone or are currently participating in clinical trials for treatment;
- Serious or uncontrolled medical diseases (i.e. uncontrolled diabetes, chronic kidney disease, chronic lung disease or uncontrolled active infection, mental diseases/social conditions that limit the compliance with the research requirements) that the researchers think will confuse the research treatment response analysis;
- Pregnant or lactating patients, or any patients with fertility, have not taken appropriate pregnancy prevention measures.

## Locations (1 total)

---

Tianjin Medical University Second Hospital, Tianjin, Tianjin Municipality, China